Intestinal Permeability Test: Endpoints for a Stalled Gut Protocol

The intestinal permeability test to use is the dual-sugar lactulose-to-mannitol ratio, ordered through gastroenterology or a reference laboratory, not serum zonulin. Measure it before a repair protocol starts and set the repeat date in advance; the controlled glutamine trial remeasured at the end of its eight-week course.

A patient who plateaus on a gut repair plan needs an endpoint, not another supplement. The dual-sugar test supplies one, and the metabolic terrain around the barrier deserves the same discipline.

An intestinal permeability test earns its place when a patient has addressed the obvious drivers and still has not recovered. Chapter 29 of The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, is presented in the video above, A Plateau Is Not a Personality, through a patient about sixty percent improved for five months whose lactulose-to-mannitol ratio stayed elevated after medications, sleep, diet and bile flow had been corrected. The argument is methodological: a measured baseline, doses matched to the trials that tested them, and a remeasurement date fixed before treatment begins.

Serum zonulin is not a permeability measure

Three independent validation studies set the widely used commercial zonulin kit against measured permeability: R = 0.11 in 38 subjects, R = 0.17 in 71 and R = 0.033 in 24, none significant, 133 people in all. The kits were built against the first published zonulin sequence, later shown to be unrelated to the protein, and in serum from 376 members of the Sorbs cohort none of the proteins the antibody captured corresponded to pre-haptoglobin-2. Alessio Fasano, who first described zonulin, co-authored that correction. The reviewers’ recommendation was dual-sugar assays and tissue-level measures, and because pre-haptoglobin-2 is not naturally expressed in mice, rodent serum zonulin findings inherit the problem.

How the dual-sugar intestinal permeability test works, and why it is repeated

Mannitol, the smaller probe, crosses transcellularly and reflects absorptive surface; lactulose crosses paracellularly when junctions loosen. Neither is metabolized, both are excreted in urine over roughly six hours, and the ratio cancels gastric emptying, ingested volume and renal clearance. It is cumbersome and produces no colored report, but it measures the barrier. It is not a Measura test; it is ordered through gastroenterology or a reference laboratory.

Repetition is the point. In the case above the ratio returned to range at twelve weeks; those are practice-reported figures from our own population, not trial outcomes, and individual results vary. Symptom reports are a weak substitute. In a three-arm, open-label polaprezinc eradication trial run across 11 Chinese cities, all arms reported significant symptom improvement at 7, 14 and 28 days, including the arm that received antibiotics alone.

Enrollment determines effect size

Glutamine shows why selection matters. In adults with post-infectious diarrhea-predominant IBS and documented hyperpermeability, 5 g three times daily for eight weeks produced a fifty-point symptom response in 79.6% against 5.8% on placebo, and the lactulose-to-mannitol ratio fell from 0.11 to 0.05, returning to range only in the treated group. A meta-analysis of 39 human glutamine studies, largely in surgical and critically ill patients, found a pooled ratio change of 0.01. The single trial’s effect is much larger because it admitted only patients with a measured leak, excluding everyone with nothing to fix. It comes from one group without replication, and its authors asked for validating trials.

Dr. Padda spent years telling patients that a lining which renews in days needs only rest and time. That holds for acute injury. For a barrier measured open over years, the screening implication is direct: measuring before treating selects the patients most likely to respond and supplies the endpoint that makes a response interpretable.

Dose provenance and endpoint mismatch

Several agents common in gut protocols carry doses from trials that never measured the barrier. Zinc carnosine prevented an indomethacin-induced permeability rise in 10 healthy volunteers at 37.5 mg twice daily, while the 75 mg twice-daily retail dose derives from Helicobacter pylori eradication trials; doubling to 150 mg twice daily added no eradication benefit as adverse events rose from 2.8% to 5.1%. Oral GABA doses come from stress and sleep research, and none of the 14 included studies measured a gastrointestinal endpoint. Larazotide acetate, the only junction-targeted drug taken to phase 3, did not separate from placebo on the dual-sugar ratio in pooled analysis, and phase 3 was terminated without a published efficacy figure. Symptom relief and measured permeability can dissociate, and agent selection remains with the treating clinician.

Nutrient status and the metabolic terrain

Supply deficits are checkable. The global estimate that 17.3% of people are at risk of inadequate zinc intake is a food-supply model; risk rose with the phytate-to-zinc ratio and fell with animal-source zinc, and its authors called for direct biochemical assessment instead of inference. A randomized trial gave 27 Crohn’s patients in remission vitamin D at 2,000 IU a day; permeability held steady on treatment while the placebo arm worsened, and those reaching 75 nmol/L had lower CRP (p = 0.019), a post-hoc responder analysis that favors dosing to a measured level. Glycine synthesis plus diet falls about 10 g a day short of demand in a 70 kg adult, a flux calculation rather than a demonstrated deficiency. The economic driver is the food supply itself: low-priced grain and legume staples carry their own zinc blocker.

The patient who plateaus is also the patient trials exclude, with metabolic disease, a long medication list and disrupted sleep. That is where Measura [Cardiometabolic and Autonomic Health Analysis] applies. It does not measure intestinal permeability. It measures the terrain: laboratory panels for insulin resistance and inflammation, the metaflammation that travels with barrier failure; bioimpedance body composition for lean mass in patients whose diets have narrowed; and indirect calorimetry for measured resting energy expenditure, so nutrition plans for a rebuilding barrier rest on measured demand rather than an estimate. In the book’s language the gut is the first brain and the skull holds the second brain, and these measures describe the metabolic environment both share.

Selection criteria and documentation

Written selection criteria can flag patients with persistent gastrointestinal symptoms plus metabolic risk factors for cardiometabolic measurement, and standing orders keep that consistent. A baseline and a predefined repeat interval, documented through getting results into the record, turn a plateau into a trackable course. The patient version is how long it takes to heal leaky gut; the bile acid workup precedes it in postcholecystectomy diarrhea; and the full study data with limits are in the Chapter 29 companion.

Frequently asked questions

When is an intestinal permeability test worth ordering?

When a gastrointestinal plateau persists after identifiable drivers such as medications, sleep, diet and bile flow have been addressed, or before a repair protocol begins so there is an endpoint to return to. A dual-sugar ratio with a scheduled repeat distinguishes an open barrier from a slow symptomatic recovery. The case for measuring before managing is set out in clinical rationale.

Does Measura perform dual-sugar permeability testing?

No. The lactulose-to-mannitol test is ordered through gastroenterology or a reference laboratory. Measura measures the surrounding terrain, including laboratory panels for insulin resistance and inflammation, body composition and resting energy expenditure, and returns findings to the ordering physician. How these measures fit different practice types is described in specialty applications.

How soon should permeability be remeasured?

Set the interval before treatment starts and match it to the protocol being tested. The controlled glutamine trial remeasured at the end of its eight-week course, which is a defensible default for that intervention. A symptom diary alone is unreliable, since open-label trials show improvement in every arm. Tracking values across that interval is covered in chronic care and between-visit monitoring.

Should zinc and vitamin D status be checked before a gut repair protocol?

The sources favor measurement over assumption. The global zinc estimate is a food-supply model whose authors asked for direct biochemical assessment, and the vitamin D trial in Crohn’s disease pointed to a blood level of 75 nmol/L rather than a fixed dose. Laboratory results read in context are discussed in interpreting the report.

Why add indirect calorimetry or body composition for a gut patient?

Patients on long gut protocols often narrow their diets, and a barrier under repair depends on substrate supply. Measured resting energy expenditure shows whether intake meets demand, and body composition shows whether lean mass is holding. Both give the plateau a metabolic baseline alongside the permeability endpoint. The difference between measured and predicted energy use is covered in measured versus estimated metabolic rate.

Give every protocol an endpoint

Learn how the Measura protocol adds laboratory, body composition and resting metabolic rate measurement to the follow-up your practice already schedules.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Massier, L., Chakaroun, R., Kovacs, P., & Heiker, J. T. (2021). Blurring the picture in leaky gut research: How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability. Gut, 70(9), 1801-1802. https://doi.org/10.1136/gutjnl-2020-323026
Scheffler, L., Crane, A., Heyne, H., Tönjes, A., Schleinitz, D., Ihling, C. H., Stumvoll, M., Freire, R., Fiorentino, M., Fasano, A., Kovacs, P., & Heiker, J. T. (2018). Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Frontiers in Endocrinology, 9, 22. https://doi.org/10.3389/fendo.2018.00022
Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N. (2019). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut, 68(6), 996-1002. https://doi.org/10.1136/gutjnl-2017-315136
Arribas-López, E., Zand, N., Ojo, O., Snowden, M. J., & Kochhar, T. (2021). The effect of amino acids on wound healing: A systematic review and meta-analysis on arginine and glutamine. Nutrients, 13(8), 2498. https://doi.org/10.3390/nu13082498
Mahmood, A., FitzGerald, A. J., Marchbank, T., Ntatsaki, E., Murray, D., Ghosh, S., & Playford, R. J. (2006). Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut, 56(2), 168-175. https://doi.org/10.1136/gut.2006.099929
Tan, B., Luo, H.-Q., Xu, H., Lv, N.-H., Shi, R.-H., Luo, H.-S., Li, J.-S., Ren, J.-L., Zou, Y.-Y., Li, Y.-Q., Ji, F., Fang, J.-Y., & Qian, J.-M. (2017). Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One, 12(4), e0175625. https://doi.org/10.1371/journal.pone.0175625
Hepsomali, P., Groeger, J. A., Nishihira, J., & Scholey, A. (2020). Effects of oral gamma-aminobutyric acid (GABA) administration on stress and sleep in humans: A systematic review. Frontiers in Neuroscience, 14, 923. https://doi.org/10.3389/fnins.2020.00923
Hoilat, G. J., Altowairqi, A. K., Ayas, M. F., Alhaddab, N. T., Alnujaidi, R. A., Alharbi, H. A., Alyahyawi, N., Kamal, A., Alhabeeb, H., Albazee, E., Almustanyir, S., & Abu-Zaid, A. (2022). Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology, 46(1), 101782. https://doi.org/10.1016/j.clinre.2021.101782
Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: Results based on zinc availability in national food supplies and the prevalence of stunting. PLoS One, 7(11), e50568. https://doi.org/10.1371/journal.pone.0050568
Raftery, T., Martineau, A. R., Greiller, C. L., Ghosh, S., McNamara, D., Bennett, K., Meddings, J., & O’Sullivan, M. (2015). Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United European Gastroenterology Journal, 3(3), 294-302. https://doi.org/10.1177/2050640615572176